Julie Yoo
Julie Yoo is a general partner on the Bio + Health team at Andreessen Horowitz (a16z), where she leads investments in companies transforming healthcare access, payment, and delivery. She previously co-founded and served as Chief Product Officer of Kyruus, a healthtech company that scaled to 20 million patients and over 225,000 providers before being acquired by RevSpring. She holds degrees in computer science and pre-medicine from MIT, an MS in genomics from Harvard-MIT HST, and an MBA from MIT Sloan. She is best known for her thesis that healthcare's historical underinvestment in software positions the industry to leapfrog directly to AI-native care delivery models.
“We only had really like the ERP layer with EHRs and then labor. Like we were just throwing bodies at every problem. And so in some ways, we have less of a sunk cost bias as an industry... We can actually just go directly to this agentic form of technology.”
Source→“Yes, people are waiting out the door. But if you actually look at the way that our physicians are being utilized, we're still way under 100%, which was shocking, right? We had this paradox of demand out the door.”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.